Residential College | false |
Status | 已發表Published |
APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024 | |
Lau, George1; Obi, Shuntaro2; Zhou, Jian3; Tateishi, Ryosuke4; Qin, Shukui5; Zhao, Haitao6; Otsuka, Motoyuki7; Ogasawara, Sadahisa8; George, Jacob9; Chow, Pierce K.H.10; Cai, Jianqiang11; Shiina, Shuichiro12; Kato, Naoya13; Yokosuka, Osamu14; Oura, Kyoko15; Yau, Thomas16; Chan, Stephen L.17; Kuang, Ming18; Ueno, Yoshiyuki19; Chen, Minshan20; Cheng, Ann Lii21; Cheng, Gregory22,58; Chuang, Wan Long23; Baatarkhuu, Oidov24; Bi, Feng25; Dan, Yock Young26; Gani, Rino A.27; Tanaka, Atsushi28; Jafri, Wasim29; Jia, Ji Dong30; Kao, Jia Horng31; Hasegawa, Kiyoshi32; Lau, Patrick33; Lee, Jeong Min34; Liang, Jun35; Liu, Zhenwen36; Lu, Yinying37; Pan, Hongming38; Payawal, Diana A.39; Rahman, Salimur40; Seong, Jinsil41; Shen, Feng42; Shiha, Gamal43,59,60,61; Song, Tianqiang44; Sun, Hui Chuan45; Masaki, Tsutomu15; Sirachainan, Ekaphop46; Wei, Lai47; Yang, Jin Mo48; Sallano, Jose D.49; Zhang, Yanqiao50; Tanwandee, Tawesak51; Dokmeci, AKadir52; Zheng, Shu Sen53; fan, Jia54; Fan, Sheung Tat55; Sarin, Shiv Kumar56; Omata, Masao57 | |
2024-12 | |
Source Publication | Hepatology International |
ISSN | 1936-0533 |
Volume | 18Issue:6Pages:1661-1683 |
Abstract | In Asia–Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia–Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored? |
Keyword | Hepatocellular Carcinoma Systemic Therapy Guidelines The Asian Pacific Association For The Study Of The Liver |
DOI | 10.1007/s12072-024-10732-z |
URL | View the original |
Indexed By | SCIE |
Language | 英語English |
WOS Research Area | Gastroenterology & Hepatology |
WOS Subject | Gastroenterology & Hepatology |
WOS ID | WOS:001361536900001 |
Publisher | SPRINGER, ONE NEW YORK PLAZA, SUITE 4600 , NEW YORK, NY 10004, UNITED STATES |
Scopus ID | 2-s2.0-85209718693 |
Fulltext Access | |
Citation statistics | |
Document Type | Journal article |
Collection | Faculty of Health Sciences |
Corresponding Author | Lau, George |
Affiliation | 1.Humanity and Health Clinical Trial Center, Humanity and Health Medical Group, Zhongshan Hospital, Fudan University, Shanghai, Hong Kong 2.Department of Internal Medicine, Teikyo University Chiba Medical Center, Chiba, Japan 3.Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Fudan University), Ministry of Education, Shanghai Key Laboratory of Organ Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Zhongshan Hospital, Fudan University, Shanghai, China 4.Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 5.Cancer Centre of Jinling Hospital, Nanjing University of Chinese Medicine, Nanjing, China 6.Department of Liver Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & amp; Peking Union Medical College, Beijing, China 7.Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, 700-8558, Japan 8.Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, 1-8-1 Inohana, Chuo-Ku, 260-8670, Japan 9.Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Westmead, 2145, Australia 10.Department of HPB Surgery and Transplantation, Duke-NUS Medical School, National Cancer Center Singapore and Singapore General Hospital, Surgery Academic Clinical Program, Singapore, Singapore 11.Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China 12.Department of Gastroenterology, Juntendo University, Bunkyo-Ku, 2-1-1, Hongo, Tokyo, 113-8421, Japan 13.Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Chiba, Japan 14.Department of Gastroenterology, Graduate School of Medicine, Chiba University, Chiba, Japan 15.Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Miki, 1750-1 Ikenobe, Kita, Kagawa, 761-0793, Japan 16.Department of Medicine, The University of Hong Kong, Hong Kong 17.Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Centre for Cancer, The Chinese University of Hong Kong, Hong Kong 18.Center of Hepato-Pancreato-Biliary Surgery, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China 19.Faculty of Medicine, Department of Gastroenterology, Faculty of Medicine, Yamagata University, Yamagata, 2-2-2 Iida-Nishi, 990-9585, Japan 20.Department of Liver Surgery, Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, China 21.Department of OncologyDepartment of Medical OncologyGraduate Institute of OncologyDepartment of Internal Medicine, National Taiwan University Cancer CenterNational Taiwan University HospitalNational Taiwan University College of Medicine, Taipei, Taiwan 22.Humanity and Health Clinical Trial Center, Humanity & amp; Health Medical Group, Hong Kong 23.Hepatobiliary Division, Department of Internal Medicine, and Hepatitis Center, Center for Infectious Disease and Cancer Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 24.School of Medicine, Mongolian National University of Medical Sciences, Ulan Bator, Mongolia 25.Department of Medical Oncology, Laboratory of Molecular Targeted Therapy in Oncology, West China Hospital, Sichuan University, Chengdu, China 26.Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore 27.Hepatobiliary Division, Staff Medic Group of Internal Medicine, Faculty of Medicine, Universitas Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta, 10430, Indonesia 28.Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan 29.The Aga Khan University Hospital, Karachi, Pakistan 30.Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China 31.Department of Internal Medicine Division of Gastroenterology and Hepatology, Department of Internal MedicineHepatitis Research Center, Graduate Institute of Clinical Medicine, National Taiwan University Hospital Bei-Hu BranchNational Taiwan University HospitalNational Taiwan University College of Medicine, Taipei, Taiwan 32.Department of Surgery, Graduate School of Medicine, Hepato-Biliary-Pancreatic Surgery Division, The University of Tokyo, Tokyo, Japan 33.Humanity and Health Clinical Trial Center, Humanity & Health Medical Group, Hong Kong SAR, China 34.Department of Radiology, Seoul National University College of Medicine, Seoul, South Korea 35.Department of Medical Oncology, Peking University International Hospital, Beijing, China 36.Senior Department of Hepatology, The Fifth Medical Center of Chinese People’s Liberation, Army General Hospital, Beijing, China 37.Department of Comprehensive Liver Cancer Center, The Fifth Medical Center of Chinese, PLA General Hospital, Beijing, China 38.Department of Medical Oncology, College of Medicine, Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, China 39.Department of Medicine, Fatima University Medical Center, Manila, Philippines 40.Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh 41.Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea 42.Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University (Navy Medical University), Shanghai, China 43.European Liver Patients’ Association (ELPA), Brussels, Belgium 44.Department of Hepatobiliary, HCC Research Center for Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China 45.Department of Liver Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China 46.Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand 47.Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, Tsinghua University, Beijing, China 48.Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea 49.Section of Gastroenterology, University of Santo Tomas, Manila, Philippines 50.Department of Gastrointestinal Medical Oncology, Institute of Prevention and Treatment of Cancer of Heilongjiang Province, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China 51.Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand 52.Department of Medicine, Ankara University School of Medicine, Ankara, Turkey 53.Department of Hepatobiliary and Pancreatic Surgery, Department of Liver Transplantation, Shulan (Hangzhou) Hospital, Zhejiang Shuren University School of Medicine, Hangzhou, China 54.Department of Liver Surgery and Transplantation, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China 55.Liver Surgery and Transplant Centre, Hong Kong Sanatorium and Hospital, Hong Kong 56.Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India 57.Department of Gastroenterology, Yamanashi Prefectural Center Hospital, Kofu-City, Yamanashi, Japan 58.Faculty of Health Sciences, University of Macau, Macao SAR, China 59.World Hepatitis Alliance, London, United Kingdom 60.African Liver Patient Association (ALPA), Cairo, Egypt 61.The Association of Liver Patients Care (ALPC), Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egyptian Liver Research Institute and Hospital (ELRIAH), El Mansoura, Sherbin, Egypt |
Recommended Citation GB/T 7714 | Lau, George,Obi, Shuntaro,Zhou, Jian,et al. APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024[J]. Hepatology International, 2024, 18(6), 1661-1683. |
APA | Lau, George., Obi, Shuntaro., Zhou, Jian., Tateishi, Ryosuke., Qin, Shukui., Zhao, Haitao., Otsuka, Motoyuki., Ogasawara, Sadahisa., George, Jacob., Chow, Pierce K.H.., Cai, Jianqiang., Shiina, Shuichiro., Kato, Naoya., Yokosuka, Osamu., Oura, Kyoko., Yau, Thomas., Chan, Stephen L.., Kuang, Ming., Ueno, Yoshiyuki., ...& Omata, Masao (2024). APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. Hepatology International, 18(6), 1661-1683. |
MLA | Lau, George,et al."APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024".Hepatology International 18.6(2024):1661-1683. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment